



Aplicación del sistema experto SeDeM a la optimización de la fabricación de medicamentos según ICH Q8, Q9 y Q10

Daniel Puñal Peces

ADVERTIMENT. La consulta d'aquesta tesi queda condicionada a l'acceptació de les següents condicions d'ús: La difusió d'aquesta tesi per mitjà del servei TDX (www.tdx.cat) i a través del Dipòsit Digital de la UB (diposit.ub.edu) ha estat autoritzada pels titulars dels drets de propietat intel·lectual únicament per a usos privats emmarcats en activitats d'investigació i docència. No s'autoritza la seva reproducció amb finalitats de lucre ni la seva difusió i posada a disposició des d'un lloc aliè al servei TDX ni al Dipòsit Digital de la UB. No s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX o al Dipòsit Digital de la UB (framing). Aquesta reserva de drets afecta tant al resum de presentació de la tesi com als seus continguts. En la utilització o cita de parts de la tesi és obligat indicar el nom de la persona autora.

ADVERTENCIA. La consulta de esta tesis queda condicionada a la aceptación de las siguientes condiciones de uso: La difusión de esta tesis por medio del servicio TDR (www.tdx.cat) y a través del Repositorio Digital de la UB (diposit.ub.edu) ha sido autorizada por los titulares de los derechos de propiedad intelectual únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con finalidades de lucro ni su difusión y puesta a disposición desde un sitio ajeno al servicio TDR o al Repositorio Digital de la UB. No se autoriza la presentación de su contenido en una ventana o marco ajeno a TDR o al Repositorio Digital de la UB (framing). Esta reserva de derechos afecta tanto al resumen de presentación de la tesis como a sus contenidos. En la utilización o cita de partes de la tesis es obligado indicar el nombre de la persona autora.

WARNING. On having consulted this thesis you're accepting the following use conditions: Spreading this thesis by the TDX (www.tdx.cat) service and by the UB Digital Repository (diposit.ub.edu) has been authorized by the titular of the intellectual property rights only for private uses placed in investigation and teaching activities. Reproduction with lucrative aims is not authorized nor its spreading and availability from a site foreign to the TDX service or to the UB Digital Repository. Introducing its content in a window or frame foreign to the TDX service or to the UB Digital Repository is not authorized (framing). Those rights affect to the presentation summary of the thesis as well as to its contents. In the using or citation of parts of the thesis it's obliged to indicate the name of the author.

UNIVERSITAT DE BARCELONA
FACULTAT DE FARMÀCIA
DEPARTAMENT DE FARMÀCIA I TECNOLOGIA FARMACÈUTICA

APLICACIÓN DEL SISTEMA EXPERTO SeDeM A LA
OPTIMIZACIÓN DE LA FABRICACIÓN DE
MEDICAMENTOS SEGÚN ICH Q8, Q9 Y Q10

DANIEL PUÑAL PECES
2014

6.- BIBLIOGRAFÍA

- Agrawal R, Naveen Y. Pharmaceutical Processing – A Review on Wet Granulation Technology. *Int J Pharm Front Res.* 2011; 1(1): 65–83.
- Aguilar JE. Aportación al estudio tecnológico de comprimidos bucodispersables por compresión directa. Tesis doctoral. Facultad de Farmacia. Barcelona. Universidad de Barcelona. 2010.
- Aguilar-Díaz JE, García-Montoya E, Pérez-Lozano P, Suñé-Negre JM, Miñarro M, Ticó JR. The use of the SeDeM diagram expert system to determine the suitability of diluents-disintegrants for direct compression and their use in formulation of ODT. *Eur J Pharm Biopharm.* 2009; 73: 414–423.
- Aguilar-Díaz JE, García-Montoya E, Suñé-Negre JM, Pérez-Lozano P, Miñarro M, Ticó JR. Predicting orally disintegrating tablets formulations of ibuprofen tablets. An application of the new SeDeM-ODT expert system. *Eur J Pharm Biopharm.* 2012; 80: 638-648.
- Aguilar JE, García Montoya E, Pérez Lozano P, Suñé Negre JM, Miñarro Carmona M, Ticó JR. SeDeM expert system a new innovator tool to develop pharmaceutical forms. *Drug Dev Ind Pharm.* 2014; 40(2): 222-236.
- Aksu B, Aydoğan M, Kanik B, Aksoy E. A Flexible Regulatory Approach for Different Raw Materials Suppliers Using QbD Principles. *Research Journal of Pharmaceutical, Biological and Chemical Sciences.* 2013. Octubre-Diciembre; 4 (4): 358-372.
- Allen LV Jr. Featured excipient: capsule and tablet diluents. *Int J Pharm Compound.* 2000; 4 (4): 306–310, 324–325.
- Alpar O, Hersey JA, Shotton E. The compressions properties of lactose. *J Pharm Pharmacol* 1970; 22 (Suppl.): 1S–7S.
- Altamirano Carmona E, Barbosa Rodríguez R. Inteligencia Artificial – Sistemas de experto. Disponible en: <http://www.slideshare.net/ruttbar/sistemas-expertos-4637427>; último acceso: Julio 2014.
- Ansel HC, Allen LV, Popovich NG, editores. *Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems.* 8ª Edición. Philadelphia. Lea & Febiger. 2004.
- Armstrong NA, Patel A, Jones TM. The compressional properties of dextrose monohydrate and anhydrous dextrose of varying water contents. En: Rubinstein MH. *Pharmaceutical Technology: Tableting Technology*, vol. 1. Chichester. Ellis Horwood. 1987: 127–138.
- Artalejo-Ortega B, Bamio-Nuñez A, del Pozo-Carrascosa A, Faulí-Trillo C. Evaluación de la dureza de los comprimidos en función del tipo de durómetro empleado. *Cir Far.* 1992; 315: 239-248.
- Ayorinde JO, Odeku OA, Itiola OA. The survival of *B. subtilis* spores in dicalcium phosphate, lactose, and corn starch and their binary mixtures during tableting. *Pharmaceutical Technology.* 2005; 29(12): 56–67.

- Bacher C, Olsen PM, Bertelsen P, Kristensen J, Sonnergaard JM. Improving the compaction properties of roller compacted calcium carbonate. *Int J Pharm.* 2007; 342: 115–123.
- Baldinger A, Clerdent L, Rantanen J, Yang M, Grohganz H. *Pharmaceutical Development and Technology.* 2012; 17(4): 389–397.
- Banker GS, Anderson NR. Tablets. En: Lachman L, Lieberman HA, Kaning JL, editores. *The theory and practice of industrial pharmacy.* 3ª Ed. Philadelphia. Lea & Febiger. 1986: 293-345.
- Banker GS, Peck GE, Valey G. Tablet formulation and design. En: Lieberman HA, Lachman L, editores. *Pharmaceutical dosage forms: Tablets.* Vol I. New York. Marcel Dekker, Inc. 1980: 61-108.
- Basedow AM, Möschl GA. Sorbitol instant – an excipient with unique tableting properties. *Drug Dev Ind Pharm.* 1986; 12: 2061–2089.
- Bauer H, Herkert T, Bartels M, Kovar KA, Schwarz E, Schmidt PC. Investigations on polymorphism of mannitol/sorbitol mixtures after spray drying using differential scanning calorimetry, x-ray diffraction and near infrared spectroscopy. *Pharm Ind.* 2000; 62(3): 231–235.
- Beck M, Tomka I. On the equation of state of plasticized ethyl cellulose of varying degrees of substitution. *Macromolecules.* 1996; 29(27): 8759–8766.
- Beneyto J, Manzano T. Las ICH Q8, Q9, Q10 y Q11: el hilo conductor de la Nueva Industrialización. *FarmaEspaña Industrial.* 2012; Julio/Agosto: 14-16.
- Beneyto J. La mejora continua en la industria farmacéutica. *Industria Farmacéutica.* 2007; Julio-Agosto (nº 134): 72-85.
- Bentley P. Products Formulation expert system (PFES). En Rowe RC, Roberts RJ, editores. *Intelligent software for product formulation.* London. Taylor and Francis. 1998: 27-41.
- Bhattachar SN, Hedden DB, Olsofsky AM, Qu X, Hsieh WY, Canter, KG. Evaluation of the vibratory feeder method for assessment of powder flow properties. *Int J Pharm.* 2004; 269: 385–392.
- Blanco M. Técnicas instrumentales en PAT. Procedente de: Institute for Life Long Learning (IL3): Tecnología Analítica de Procesos (PAT); 2007 Marzo; Barcelona (España). Referencia (a).
- Blanco M. Como pasar de las ICH guidelines a PAT. Procedente de: Institute for Life Long Learning (IL3): Tecnología Analítica de Procesos (PAT); 2007 Marzo; Barcelona (España). Referencia (b).
- Blaug SM, Huang W. Interaction of dextroamphetamine sulfate with spray-dried lactose. *J Pharm Sci.* 1972; 61: 1770–1775.
- Bodhmag A. Correlation between physical properties and flowability indicators for fine powders. Tesis doctoral. Facultad de Ingeniería Química. Saskatoon. Universidad de Saskatchewan. 2006.

- Bodmeier R, Paeratakul O. The effect of curing on drug release and morphological properties of ethylcellulose pseudolatex-coated beads. *Drug Dev Ind Pharm.* 1994; 20 (9): 1517–1533.
- Bolhuis GK, Lerk CF. Comparative evaluation of excipients for direct compression. *Pharm Weekbl.* 1973; 108: 469–481.
- Bolhuis GK, Van Kamp HV, Lerk CF, Gielen JW, Arends AW, Stuit GJ. Effect of variation of degree of substitution, crosslinking and purity on the disintegrant efficiency of sodium starch glycolate. *Acta Pharm Technol.* 1984; 30: 24–32.
- Bolhuis GK, Zuurman K, Te Wierik GHP. Improvement of dissolution of poorly soluble drugs by solid deposition on a super disintegrant. Part 2. Choice of super disintegrants and effect of granulation. *Eur J Pharm Sci.* 1997; 5(2): 63–69.
- Bolton S, Atluri R. Crystalline sorbitol tablets: effect of mixing time and lubricants on manufacturing. *Drug Cosmet Ind.* 1984; 135 (5): 44-50.
- Bos CE, Bolhuis GK, Van Doorne H, Lerk CF. Native starch in tablet formulations: properties on compaction. *Pharm Weekbl Sci.* 1987; 9: 274–282.
- Botha SA, Lötter AP, Du Preez JL. DSC screening for drug–excipient and excipient–excipient interactions in polypharmaceuticals intended for the alleviation of the symptoms of colds and flu. III. *Drug Dev Ind Pharm.* 1987; 13 (7): 1197–1215.
- Botzolakis JE, Augsburg LL. Disintegrating agents in hard gelatin capsules part 1: mechanism of action. *Drug Dev Ind Pharm.* 1988; 14 (1): 29–41.
- Bouffard J, Kaster M, Dumont H. Influence of processing variables and physicochemical properties on the granulation mechanisms of mannitol in a fluid bed top spray granulator. *Drug Dev Ind Pharm.* 2005; 31: 923–933.
- Boukouvala F, Muzzio F, Ierapetritou M. Design space of pharmaceutical processes using data-driven-based methods. *J Pharm Innov.* 2010; 5(3): 119-137.
- Brittain HG. On the physical characterization of pharmaceutical solids. *Pharm. Technol.* 1997; 1: 100-106.
- British Pharmacopoeia (BP) 2014. London. The Stationary Office. 2014.
- Brown AM, Masson E. Hidden sorbitol in proprietary medicines – a cause for concern? *Pharm J.* 1990; 245: 211.
- Bryan JW, McCallister JD. Matrix forming capabilities of three calcium diluents. *Drug Dev Ind Pharm.* 1992; 18 (19): 2029–2047.
- Burggraaf J, Schoemaker RC, Lentjes EGWM, Cohen AF. Sorbitol as a marker for drug-induced decreases of variable duration in liver blood flow in healthy volunteers. *Eur J Pharm Sci.* 2000; 12: 133–139.

- Cal S, Iglesias G, Souto C, Concheiro A, Gomez-Amoza JL, Martinez-Pacheco R. Effects of hydration on the properties of a roller-dried β -lactose for direct compression. *Int J Pharm.* 1996; 129: 253–261.
- Callahan JC, Cleary GW, Elefant M, Kaplan G, Kensler T, Nash RA. Equilibrium moisture content of pharmaceutical excipients. *Drug Dev Ind Pharm.* 1982; 8: 355–369.
- Caramella C, Colombo P, Conte U, La Manna A. The influence of disintegrants on the characteristics of coated acetylsalicylic acid tablets. *Farmaco.* 1978; 33 (11): 498– 507.
- Cariño R. Tendencias tecnológicas. 2002; *Boletín IIE*, julio-agosto.
- Carmargo IM, Saiki M, Vasconcellos MB, Avila DM. Abrasiveness evaluation of silica and calcium carbonate used in the production of dentifrices. *J Cos Sci.* 2001; 52: 163–167.
- Carstensen JT, Ertell C. Physical and chemical properties of calcium phosphates for solid state pharmaceutical formulations. *Drug Dev Ind Pharm.* 1990; 16 (7): 1121–1133.
- Casadio S. *Tecnología Farmacéutica Vol I.* 2ª Ed. Milan. Cisalpino-Goliardica. 1972.
- Casalderrey M, Souto C, Concheiro A, Gómez-Amoza JL, Martínez-Pacheco R. A comparison of drug loading capacity of cellactose with two ad hoc processed lactose-cellulose direct compression excipients. *Chem Pharm Bull (Tokyo).* 2004; 52(4): 398–401.
- Castello RA, Mattocks AM. Discoloration of tablets containing amines and lactose. *J Pharm Sci.* 1962; 51: 106–108.
- Cavatur RK, Vemuri NM, Pyne A, Chrzan Z, Toledo-Velasquez D, Suryanarayanan R. Crystallization behavior of mannitol in frozen aqueous solutions. *Pharm Res.* 2002; 19: 894–900.
- CDER: Center for Drug Evaluation and Research. Guidance for Industry Immediate – Release Solid Oral Dosage Forms. United States - Food and Drug Administration. 1995. Disponible en: <http://www.gmp-compliance.org/guidemgr/files/1-6-8.PDF>; último acceso: Julio 2014.
- Celik M. Compaction of multiparticulate oral dosage forms. En: Ghebre-Sellassie I, editor. *Multiparticulate Oral Drug Delivery.* New York. Marcel Dekker. 1994: 181–215.
- Celik M, Okutgen E. A feasibility study for the development of a prospective compaction functionality test and the establishment of a compaction data bank. *Drug Dev Ind Pharm.* 1993; 19: 2309–2334.
- Cervera MF, Heinämäki J, Krogars K, Jörgensen AC, Karjalainen M, Colarte AI, Yliruusi J. Solid state and mechanical properties of aqueous chitosan-amylose starch films plasticized with polyols. *AAPS Pharm Sci Tech.* 2004; 5(1): E15.

- Charoo NA, Ali AA. Quality risk management in pharmaceutical development. *Drug Development and Industrial Pharmacy*. 2013; Vol. 39, no. 7: 947-960.
- Charoo NA, Shamsheer AAA, Zidan AS, Rahman Z. Quality by design approach for formulation development: A case study of dispersible tablets. *International Journal of Pharmaceutics*. 2012; 423: 167– 178.
- Chemnet: Almotriptán. Disponible en: <http://www.chemnet.com/cas/es/181183-52-8/Almotriptan.html>; último acceso: Mayo 2014.
- Chilamkurti RN, Rhodes CT, Schwartz JB. Some studies on compression properties of tablet matrices using a computerized instrumented press. *Drug Dev Ind Pharm*. 1982; 8: 63–86.
- Chowhan ZT, Chi LH. Drug–excipient interactions resulting from powder mixing III: solid state properties and their effect on drug dissolution. *J Pharm Sci*. 1986; 75: 534–541. Referencia (a).
- Chowhan ZT, Chi LH. Drug–excipient interactions resulting from powder mixing IV: role of lubricants and their effect on in vitro dissolution. *J Pharm Sci*. 1986; 75: 542–545. Referencia (b).
- Cid E, Jaminet F. Influence of adjuvants on the dissolution rate and stability of acetylsalicylic acid in compressed tablets. *J Pharm Belg*. 1971; 26: 38–48 [in French].
- Claudius JS, Neau SH. Kinetic and equilibrium characterization of interactions between glycopeptide antibiotics and sodium carboxymethyl starch. *Int J Pharm*. 1996; 144: 71–79.
- Claudius JS, Neau SH. The solution stability of vancomycin in the presence and absence of sodium carboxymethyl starch. *Int J Pharm*. 1998; 168: 41–48.
- Coello J. Diseño experimental. Técnicas de screening (cribado). Procedente de: Institute for Life Long Learning (IL3): Tecnología Analítica de Procesos (PAT); 2007 Marzo; Barcelona (España). Referencia (a).
- Coello J., Tratamiento multivariante de datos. Factor análisis. Procedente de: Institute for Life Long Learning (IL3): Tecnología Analítica de Procesos (PAT); 2007 Marzo; Barcelona (España) Referencia (b).
- Colorcon. Technical bulletin: Starch 1500®. BPSI Holdings LLC. 2012. Disponible en: http://www.colorcon.com/literature/marketing/ex/Starch%201500/Tech%20Bulletin_Starch1500_properties.pdf; último acceso: Mayo 2014.
- Cordoba-Diaz M, Cordoba-Borrego M, Cordoba-Diaz D. Influence of pharmacotechnical design on the interaction and availability of norfloxacin in directly compressed tablets with certain antacids. *Drug Dev Ind Pharm* 2000; 26: 159–166.

- Dahlinger LE, Johansson M, Sjogre J. Comparison of methods for evaluation of flow properties of powder and granulates. *Drug Dev Ind Pharm.* 1982; 8: 455-461.
- Danckwerts MP, Ebrahim S, Pillay V. Pharmaceutical formulation of a fixed-dose antituberculosis combination. *Int J Tuberc Lung D* 2003; 7: 289–297.
- Daoust RG, Lynch MJ. Mannitol in chewable tablets. *Drug Cosmet Ind.* 1963; 93 (1): 26–28, 88, 92, 128–129.
- Davies PN et al. Some pitfalls in accelerated stability testing with tablet and capsule lubricants. *J Pharm Pharmacol.* 1987; 39: 86P.
- Debord B, Lefebvre C, Guyot-Hermann AM, Hubert J, Bouché R, Cuyot JC. Study of different crystalline forms of mannitol: comparative behaviour under compression. *Drug Dev Ind Pharm.* 1987; 13: 1533–1546.
- Denoel A, Jaminet FR. *Pharmacie Galénique. Tome III. Liege. Les presses universitaires de Liège.* 1971.
- Dodick DW, Martin V. Triptans and CNS side effects: pharmacokinetic and metabolic mechanisms. *Cephalalgia.* 2004; Jun 24 (6):417-24.
- DOUE: Diario Oficial de la Unión Europea. Guía sobre modificaciones de los términos de las autorizaciones de comercialización de medicamentos de uso humano y medicamentos veterinarios. Serie C: C 223. Páginas: 35-61. Edición en lengua española. Agosto 2013. ISSN 1977-09284.
- Dressman JB, Derbin GM, Ismailos G, Jarvis C, Ozturk AG, Palsson BO, Wheatley TA. Circumvention of pH-dependent release from ethyl cellulose-coated pellets. *J Control Release.* 1995; 36(3): 251–260.
- Dureja H. Scale-Up and Post Approval Changes (SUPAC). 2013. Disponible en: <http://es.slideshare.net/bdvfgbdhg/scale-up-and-post-approval-changessupac>; último acceso: Julio 2014.
- Durham DG, Hung CT, Taylor RB. Identification of some acids produced during autoclaving of D-glucose solutions using HPLC. *Int J Pharm.* 1982; 12: 31–40.
- Duriez X, Joshi AA. Starches a versatile source. *Pharma Form.* 2004; Qual. 6 (3): 48-50.
- Du Ross JW. Modification of the crystalline structure of sorbitol and its effects on tableting characteristics. *Pharm Technol.* 1984; 8 (9): 42–53.
- Du Vall RN, Koshy KT, Dashiell RE. Comparative evaluation of dextrose and spray-dried lactose in direct compression systems. *J Pharm Sci.* 1965; 54: 1196–1200.
- Enézian GM. Direct compression of tablets using microcrystalline cellulose. *Pharm Acta Helv.* 1972; 47: 321–363 [in French].
- Eerikäinen S, Yliruusi J, Laakso R. The behaviour of the sodium salt of indomethacin in the cores of film-coated granules containing various fillers. *Int J Pharm.* 1991; 71: 201–211.

- El-Shattawy HH, Peck GE, Kildsig DO. Aspartame direct compression excipients: preformulation stability screening using differential scanning calorimetry. *Drug Dev Ind Pharm* 1981; 7 (5): 605–619.
- El-Shattawy HH. Ampicillin direct compression excipients: preformulation stability screening using differential scanning calorimetry. *Drug Dev Ind Pharm*. 1982; 8(6): 819–831.
- El-Shattawy HH, Kildsig DO, Peck GE. Cephalexin I direct compression excipients: preformulation stability screening using differential scanning calorimetry. *Drug Dev Ind Pharm* 1982; 8 (6): 897–909. Referencia (a).
- El-Shattawy HH Kildsig DO, Peck GE. Erythromycin direct compression excipients: preformulation stability screening using differential scanning calorimetry. *Drug Dev Ind Pharm* 1982; 8 (6): 937–947. Referencia (b).
- EMA: European Medicines Agency. ICH Topic Q8. Note for guidance on pharmaceutical development. EMEA/CHMP/167068/2004. Junio 2009. Disponible en:
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002872.pdf; último acceso: Mayo 2014.
- European Pharmacopoeia, 6ª ed. (6.1). Strasbourg (France). Council of Europe. 2008. Monografía 0478: Tablets.
- European Pharmacopoeia, 6ª ed. (6.0). Strasbourg (France). Council of Europe. 2008. Monografía 2.5.12: Water: Semi-micro determination (01/2005:20512).
- European Pharmacopoeia, 6ª ed. (6.0). Strasbourg (France). Council of Europe. 2008. Monografía 2.9.3: Disolussion test for solid dosage forms.
- European Pharmacopoeia, 7ª ed. (7.0). Strasbourg (France). Council of Europe. 2011. Monografía 2.2.32: Loss on drying.
- European Pharmacopoeia, 7ª ed. (7.0). Strasbourg (France). Council of Europe. 2011- Monografía 2.9.12: Sieve test.
- European Pharmacopoeia, 7ª ed. (7.0). Strasbourg (France). Council of Europe. 2011. Monografía 2.9.15: Apparent volume.
- European Pharmacopoeia, 7ª ed. (7.0). Strasbourg (France). Council of Europe. 2011. Monografía 2.9.16: Flowability.
- European Pharmacopoeia, 7ª ed. (7.0), Strasbourg (France). Council of Europe. 2011. Monografía 2.9.36: Angle of repose (01/2010:20936).
- European Pharmacopoeia, 7ª ed. (7.0). Strasbourg (France). Council of Europe. 2011. Monografía Sodium Starch Glycolate (Type B): 01/2008:0984. 2945-2946.
- European Pharmacopoeia, 7ª ed. (7.0). Strasbourg (France). Council of Europe. 2011. Monografía Sodium Starch Glycolate (Type C): 01/2008:1566. 2946-2947.
- European Pharmacopoeia, 8ª ed. (8.0). Strasbourg (France). Council of Europe. 2014. Monografía Calcium carbonate.

- European Pharmacopeia, 8^a ed. (8.0). Strasbourg (France). Council of Europe. 2014. Monografía Glucose, anhydrous.
- European Pharmacopeia, 8^a ed. (8.2). Strasbourg (France). Council of Europe. 2014. Monografía Tablets: 01/2014:0478.
- Eyjolfsson R. Lisinopril–lactose incompatibility. *Drug Dev Ind Pharm*. 1998; 24: 797–798.
- Faroongsarng D, Peck GE. Swelling and water reuptake of tablets. Part 3. Moisture sorption behavior of tablet disintegrants. *Drug Dev Ind Pharm*. 1994; 20: 779–798.
- Ferrari F, Geddo AW, Gazzaniaga C, Caramella C, Conte U. Water uptake to fast disintegrating tablets and Weibull function. *S.T.P. Pharma*. 1988; (6): 481-484.
- Ferreira D. Sistemas expertos: Ventajas y Desventajas. *blogspot.com* [internet]. Disponible en: <http://sistemasespertosproactivas.blogspot.com.es/p/ventajas-y-desventajas-de-los-se.html>; último acceso: Mayo 2014.
- Fischer E. Calcium phosphate as a pharmaceutical excipient. *Manuf Chem*. 1992; 64 (6): 25–27.
- Fischhoff B, Bostrom A, Quadrel M. Risk Perception and Communication. *Annual Review of Public Health*. 1993; Vol. 14: 183–203.
- Forner DF, inventor; Duran CP, inventor; Soto JP, inventor; Noverola AV, inventor; Mauri JM, inventor; Laboratorios Almirall S.A., beneficiario. Indole derivatives. United States Patent. Number: 5,565,447. 15 Octubre 1996.
- Florez J, Armijo JA, Mediavilla A, editores. *Farmacología humana*. Edición 5^a. Barcelona. Elsevier/Masson. 2008. ISBN: 9788445818619.
- Font Quer P, editor. *Medicamenta*. 6a. edición. Barcelona. Editorial Labor SA. 1962: 340-341.
- Friedman M, Harrari D, Rimer A, Stabholz A. Inhibition of plaque formation by a sustained release delivery system for cetylpyridinium chloride. *Int J Pharm*. 1988; 44: 243–247.
- García Montoya E. Optimización, validación y modelización de un proceso de fabricación de comprimidos. Desarrollo de una aplicación interactiva multimedia. Tesis doctoral. Facultad de Farmacia. Barcelona. Universidad de Barcelona, 2001.
- García Montoya E, Suñé Negre JM, Pérez Lozano P, Miñarro Carmona M, Ticó JR. Metodología de preformulación galénica para la caracterización de sustancias en relación a su viabilidad para la compresión: Diagrama SeDeM. *Farmaespaña Industrial*. 2010; enero/febrero: 58-62.
- García Sánchez MJ, SantosBuelga D, editores. *Monografías Galénicas: Formas farmacéuticas solidas (III)*. Madrid. International Marketing and Communications. 1993. ISBN: 84-7867-035-1.

- Gebre Mariam T, Winnemöller M, Schmidt PC. Evaluation of the disintegration efficiency of a sodium starch glycolate prepared from enset starch in compressed tablets. *Eur J Pharm Biopharm.* 1996; 42 (2): 124–132.
- Gohel MC, Jogani PD. A review of co-processed directly compressible excipients. *J. Pharm. Pharmaceut. Sci.* 2005; 8 (1): 76-93.
- Gokhale R, Sun Y, Shukla AJ. High-Shear Granulation. En: Parikh DM, editor. *Handbook of Pharmaceutical Granulation Technology.* 2^a Ed. Boca Raton (USA). Taylor & Francis Group. 2005: 204-216.
- Goracinova K, Klisarova L, Simov A, Fredro-kumbaradzi E, Petrusevska-tozi L. Preparation, physical characterization, mechanisms of drug/polymer interactions, and stability studies of controlled-release solid dispersion granules containing weak base as active substance. *Drug Dev Ind Pharm.* 1996; 22(3): 255–262.
- Gordon MS, Chowhan ZT. Effect of tablet solubility and hygroscopicity on disintegrant efficiency in direct compression tablets in terms of dissolution. *J Pharm Sci.* 1987; 76: 907–909.
- Gordon MS, Rudraraju VS, Dani K, Chowhan ZT. Effect of the mode of super disintegrant incorporation on dissolution in wet granulated tablets. *J Pharm Sci.* 1993; 82(2): 220–226.
- Gorecki DKJ, Richardson CJ, Pavlakidis P, Wallace SM. Dissolution rates in calcium carbonate tablets: a consideration in product selection. *Can J Pharm.* 1989; 122: 484–487, 508.
- Gungel WC, Kanig JL. Tablets. En: Lachman L, Lieberman HA, Kanig JL, editores. *The theory and practice of industrial pharmacy.* 2^a Ed. Philadelphia. Lea & Febiger. 1976: 296-320.
- Hannula AM, Marvola M, Jons M. Release of ibuprofen from hard gelatin capsule formulations: effect of modern disintegrants. *Acta Pharm Fenn.* 1989; 98: 189–196.
- Harjunen P, Lehto VP, Martimo K, Suihko E, Lankinen T, Paronen P, Järvinen K. Lactose modifications enhance its drug performance in the novel multiple dose Taifun® DPI. *Eur J Pharm Sci.* 2002; 16(4–5):313–321. Referencia (a).
- Harjunen P, Lehto VP, Väliisaari J, Paronen P, Järvinen K. Effects of ethanol to water ratio in feed solution on the crystallinity of spray dried lactose. *Drug Dev Ind Pharm.* 2002; 28 (8): 949–955. Referencia (b).
- Hasegawa M. Direct compression: microcrystalline cellulose grade 12 versus classic grade 102. *Pharm Technol.* 2002; 26 (5): 50-60.
- Hauschild K, Picker-Freyer KM. Evaluation of a new coprocessed compound based on lactose and maize starch for tablet formulation. *AAPS Pharm Sci.* 2004; 6: Article 16.

- Hegedüs A. Comparison of the effect of granulation and drying techniques on the quality of a pharmaceutical product with a high active ingredient content. Tesis doctoral. Facultad de Farmacia. Szeged. Universidad de Szeged. 2007.
- Henderson NL, Bruno AJ. Lactose USP (beadlets) and dextrose (PAF 2011): two new agents for direct compression. *J Pharm Sci.* 1970; 59: 1336–1340.
- Heng PW, Chan LW, Easterbrook MG, Li X. Investigation of the influence of mean HPMC particle size and number of polymer particles on the release of aspirin from swellable hydrophilic matrix tablets. *J Control Release.* 2001; 76 (1–2): 39–49.
- Huang J, Kaul G, Cai C, Chatlapalli R, Hernandez-Abad P, Ghosh K, Nagi A. Quality by design case study: An integrated multivariate approach to drug product and process development. *Int J Pharm.* 2009; 382: 23–32.
- Hölzer AW, Sjögren J. Evaluation of sodium stearyl fumarate as a tablet lubricant. *Int J Pharm.* 1979; 2: 145–153.
- Hölzer AW, Sjögren J. Evaluation of some lubricants by the comparison of friction coefficients and tablet properties. *Acta Pharm Suec.* 1981; 18: 139–148.
- Hwang RC, Peck GR. A systematic evaluation of the compression and tablet characteristics of various types of lactose and dibasic calcium phosphate. *Pharm Technol.* 2001; 25 (6): 54-68.
- IBM Business Consulting Services. The metamorphosis of manufacturing. From art to science. New York. 2005. Disponible en: <http://www-935.ibm.com/services/us/imc/pdf/ge510-4034-metamorphosis-of-manufacturing.pdf>; último acceso: Mayo 2014.
- Ingram JT, Lowenthal W. Mechanism of action of starch as a tablet disintegrant I: factors that affect the swelling of starch grains at 37°. *J Pharm Sci.* 1966; 55: 614–617.
- IQB: Instituto Químico Biológico. Almotriptán. 2004. Disponible en: <http://www.iqb.es/cbasicas/farma/farma04/a083.htm>; último acceso: Marzo 2014.
- Inteligencia artificial. <http://www.slideshare.net/armandorob/inteligencia-artificial-sistema-experto>; último acceso: Mayo 2014.
- International Conference of Harmonization (ICH) [internet]. Ginebra (Suiza). Disponible en: www.ich.org; último acceso: Mayo 2014.
- International Conference of Harmonization (ICH). ICH Q5A: Viral Safety evaluation of Biotechnology products derived from cell lines of human or animal origin. Ginebra (Suiza). Septiembre 1999. Disponible en: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5A_R1/Step4/Q5A_R1_Guideline.pdf; último acceso: Mayo 2014.

- International Conference of Harmonization (ICH). ICH Q5B: Quality of Biotechnological products: Analysis of the expression construct in cells used for production of R-DNA derived protein products. Ginebra (Suiza). Noviembre 1995. Disponible en: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5B/Step4/Q5B_Guideline.pdf; último acceso: Mayo 2014.
- International Conference of Harmonization (ICH). ICH Q5D: Derivation and characterization of cell substrates used for production of biotechnological/biological products. Ginebra (Suiza). Julio 1997. Disponible en: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5D/Step4/Q5D_Guideline.pdf; último acceso: Mayo 2014.
- International Conference of Harmonization (ICH). ICH Q7: Good manufacturing practice guide for active pharmaceutical ingredients. Ginebra (Suiza). Noviembre 2000. Disponible en: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf; último acceso: Mayo 2014.
- International Conference of Harmonization (ICH). ICH Q8: Pharmaceutical Development. Ginebra (Suiza). Agosto 2009. Disponible en: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf; último acceso: mayo 2014.
- International Conference of Harmonization (ICH). ICH Q9: Quality Risk Management. Ginebra (Suiza). Noviembre 2005. Disponible en: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf; último acceso: Mayo 2014
- International Conference of Harmonization (ICH). ICH Q10: Pharmaceutical Quality System. Ginebra (Suiza). Junio 2008. Disponible en: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf; último acceso: Mayo 2014.
- International Conference of Harmonization (ICH). Quality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers (R4). Ginebra (Suiza). Noviembre 2010. Disponible en: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_9_10_QAs/Q-IWG_Q_A_R4_Step4_Nov.2010.pdf; último acceso: Mayo 2014.
- International Conference of Harmonization (ICH). ICH Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities). Ginebra (Suiza). Mayo 2012. Disponible en: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q11/Q11_Step_4.pdf; último acceso: Mayo 2014.

- International Organization for Standardization. ISO 9001:2008: Quality management systems - Requirements. Ginebra (Suiza). 2008.
- Iskandarani B, Shiromani PK, Clair JH. Scale-up feasibility in high-shear mixers: determination through statistical procedures. *Drug Dev Ind Pharm.* 2001; 27: 651–657.
- Iwuagu MA, Agidi AA. The effect of bleaching on the disintegrant properties of maize starch. *STP Pharma Sci.* 2000; 10: 143–147.
- Iyer U, Hong WH, Das N, Ghebre-Sellassie I. Comparative evaluation of three organic solvent and dispersion-based ethyl cellulose coating formulations. *Pharm Technol.* 1990; 14 (9): 68–86.
- Jain NK, Rosenberg DB, Ulahannan MJ, Glasser MJ, Pitchumoni CS. Sorbitol intolerance in adults. *Am J Gastroenterol.* 1985; 80: 678–681.
- Jaiyeoba KT, Spring MS. The granulation of ternary mixtures: the effect of the stability of the excipients. *J Pharm Pharmacol.* 1980; 32: 1–5.
- Japanese Pharmacopoeia. The Sixteenth Edition. English version. 2011.
- Katikaneni P, Upadrashta SM, Neau SH, Mitra AK. Ethyl cellulose matrix controlled-release tablets of a water-soluble drug. *Int J Pharm.* 1995; 123: 119–125.
- Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. *Int J Pharm.* 1998; 172: 179–188.
- Keam SJ, Goa KL, Figgitt DP. Almotriptan: a review of its use in migraine. *Drugs.* 2002; 62 (2): 387-414. Review. Referencia (a).
- Keam SJ, Goa KL, Figgitt DP. Spotlight on almotriptan in migraine. *CNS Drugs.* 2002; 16(7): 501–507. Referencia (b).
- Kent DJ, Rowe RC. Solubility studies on ethyl cellulose used in film coating. *J Pharm Pharmacol.* 1978; 30: 808–810.
- Khan KA, Rhodes CT. Disintegration properties of calcium phosphate dibasic dihydrate tablets. *J Pharm Sci.* 1975; 64: 166–168. Referencia (a).
- Khan KA, Rhodes CT. Water-sorption properties of tablet disintegrants. *J Pharm Sci.* 1975; 64: 447–451. Referencia (b).
- Khan KA, Rooke DJ. Effect of disintegrant type upon the relationship between compressional pressure and dissolution efficiency. *J Pharm Pharmacol.* 1976; 28: 633–636.
- King RE, Schwartz JB. Formas farmacéuticas sólidas orales. En: Gennaro AR, editor. *Remington: The Science and Practice of Pharmacy.* 20.^a ed. Pennsylvania (USA). Easton: Mack Publishing Company. 2000.
- Kitamori N, Makino T. Improvement in pressure-dependent dissolution of trepibutone tablets by using intragranular disintegrants. *Drug Dev Ind Pharm.* 1982; 8: 125–139.
- Klinger GH, Ghalli ES, Porter SC, Schwartz JB. Formulation of controlled release matrices by granulation with a polymer dispersion. *Drug Dev Ind Pharm.* 1990; 16 (9): 1473–1490.

- Konkel P, Mielck JB. Associations of parameters characterizing the time course of the tableting process on a reciprocating and on a rotatory tableting machine for high-speed production. *Eur. J. Pharm. Biopharm.* 1997; 44 (3): 289-301.
- Kothari SH, Kumar V, Banker GS. Comparative evaluations of powder and mechanical properties of low crystallinity celluloses, microcrystalline celluloses, and powdered celluloses. *Int J Pharm.* 2002; 232: 69–80.
- Kottke MK, Chueh HR, Rhodes CT. Comparison of disintegrant and binder activity of three corn starch products. *Drug Dev Ind Pharm.* 1992; 18: 2207–2223.
- Krogars K, Heinaemaeki J, Karjalainen M, Rantanen J, Luukkonen P, Yliruusi J. Development and characterization of aqueous amylose-rich maize starch dispersion for film formation. *Eur J Pharm Biopharm.* 2003; 56(2): 215–221.
- Kulvanich P, Leesawat P, Patomchaiwat V. Release characteristics of the matrices prepared from co-spray-dried powders of theophylline and ethylcellulose. *Drug Dev Ind Pharm.* 2002; 28: 727–739.
- Lai FKY. A prototipe expert system for selecting pharmaceutical powder mixers. *Pharmaceutical Technology.* 1988; 12 (8): 22-31.
- Lai F K Y. Experts systems as applied to pharmaceutical technology. En: J.Swarbrick, J Boylan, editores. *Encyclopedia of Pharmaceutical Technology.* New York. Marcel Dekker. 1992; vol 5: 361-378.
- Lamberson RF, Raynor GE. Tableting properties of microcrystalline cellulose. *Manuf Chem Aerosol News.* 1976; 47 (6): 55–61.
- Lavasanifar A, Ghalandari R, Ataei Z, Zolfaghari ME, Mortazavi SA. Microencapsulation of theophylline using ethyl cellulose: In vitro drug release and kinetic modeling. *J Microencapsul* 1997; 14 (1): 91–100.
- Landín M, Martínez-Pacheco R, Gómez-Amoza JL, Souto C, Concheiro A, Rowe RC. The effect of country of origin on the properties of dicalcium phosphate dihydrate powder. *Int J Pharm.* 1994; 103: 9–18. Referencia (a).
- Landín M, Martínez-Pacheco R, Gómez-Amoza JL, Souto C, Concheiro A, Rowe RC. Dicalcium phosphate dihydrate for direct compression: characterization and intermanufacturer variability. *Int J Pharm.* 1994; 109: 1–8. Referencia (b).
- Landín M, Rowe RC, York P. Structural changes during the dehydration of dicalcium phosphate dihydrate. *Eur J Pharm Sci.* 1994; 2: 245–252. Referencia (c).
- Landín M Perezmarcos B, Casalderrey M, Martinez-Pacheco R, Gomez-Amoza JL, Souto C, Concheiro A, Rowe RC. Chemical stability of acetyl salicylic acid in tablets prepared with different commercial brands of dicalcium phosphate dihydrate. *Int J Pharm.* 1994; 107: 247–249. Referencia (d).

- Larhrib H, Zeng XM, Martin GP, Marriott C, Pritchard J. The use of different grades of lactose as a carrier for aerosolized salbutamol sulphate. *Int J Pharm.* 1999; 191 (1): 1–14.
- Lausier JM, Chiang CW, Zompa HA, Rhodes CT. Aging of tablets made with dibasic calcium phosphate dihydrate as matrix. *J Pharm Sci.* 1977; 66 (11): 1636–1637.
- Lavudu P, Rani AP, Divya C, Sekharan CB. High performance liquid chromatographic analysis of almotriptan malate in bulk and tablets. *Adv Pharm Bull.* 2013; 3 (1):183-188.
- Le Hir A, editor. *Pharmacie Galénique. Bonnes Pratiques de Fabrication des Médicament. 7^a Edición.* Paris. Masson S.A. 1997.
- Lebrun P, Krier F, Mantanus J, Grohganz H, Yang M, Rozet E, Boulanger B, Evrard B, Rantanen J, Hubert P. Design space approach in the optimization of the spray-drying process. *Eur J Pharm Biopharm.* 2012; 80: 226–234.
- Lee KJ, Kang A, Delfino JJ, West TG, Chetty D, Monkhouse DC, Yoo J. Evaluation of critical formulation factors in the development of a rapidly dispersing captopril oral dosage form. *Drug Dev Ind Pharm.* 2003; 29 (9): 967–979.
- Lerk CF, Bolhuis GK. Comparative evaluation of excipients for direct compression I. *Pharm Weekbl.* 1973; 108: 469–481.
- Lerk CF, Bolhuis GK, de Boer AH. Comparative evaluation of excipients for direct compression II. *Pharm Weekbl.* 1974; 109: 945–955.
- Lerk CF, Bolhuis GK, de Boer AH. Effect of microcrystalline cellulose on liquid penetration in and disintegration of directly compressed tablets. *J Pharm Sci.* 1979; 68: 205–211.
- Lerk CF. Consolidation and compaction of lactose. *Drug Dev Ind Pharm.* 1993; 19: 2359–2398.
- Levin M. Wet granulation: End-point determination and scale-up. <http://www.pharmstech.com> [internet]. Disponible en: <http://www.pharmstech.com/WetGranulation.pdf>; último acceso: Julio 2014.
- Levis SR, Deasy PB. Production and evaluation of size-reduced grades of microcrystalline cellulose. *Int J Pharm.* 2001; 213: 13–24.
- Liao XM, Krishnamurthy R, Suryanarayanan R. Influence of processing conditions on the physical state of mannitol – implications in freeze drying. *Pharm Res.* 2007; 24: 370– 376.
- Lin S. Studies on microencapsulation. Theophylline bioavailability after single oral-administration of sustained-release microcapsules. *Curr Ther Res Clin Exp.* 1987; 41 (4): 564–573.
- Lindvall S, Andersson NSE. Studies on a new intramuscular haematinic, iron–sorbitol. *Br J Pharmacol.* 1961; 17: 358–371.

- Lipsanen T. Process Analytical Technology Approach on Fluid Bed Granulation and Drying. Tesis doctoral. Facultad de Farmacia. Helsinki. Universidad de Helsinki. 2008.
- Loeffler GF, Ebey GC. Pharmaceutical tablet compression. En: Lieberman HA, Lachman L, editores. Pharmaceutical dosage forms: Tablets. Vol 2. 2ª Ed. New York. Marcel Dekker, Inc. 1990: 571-608.
- Lorenzo P, Moreno A, Lizasoain L, Leza JC, Moro MA, Portolés A, editores. Velázquez: Farmacología Básica y Clínica. Edición: 18º. Buenos Aires, Madrid. Editorial: Médica Panamericana. Año: 2008. ISBN: 978-84-9835-168-2.
- Lourenço V, Lochmann D, Reich G, Menezes JC, Herdling T, Schewitz, J. Eur J Pharm Biopharm. 2012; 81: 438–447.
- Lowenthal W. Mechanism of action of tablet disintegrants. Pharm Acta Helv. 1973; 48: 589–609.
- Lucas JM. The Essential Six Sigma. Quality Progress. 2002; enero: 27-31.
- Malamataris S, Goidas P, Dimitriou A. Moisture sorption and tensile strength of some tableted direct compression excipients. Int J Pharm. 1991; 68: 51–60.
- Manudhane KS, Contractor AM, Kim HY, Shangraw RF. Tableting properties of a directly compressible starch. J Pharm Sci. 1969; 58: 616–620.
- Marshall K. Solid oral dosage forms. En: Banker GS, Rhodes CT, editores. Modern Pharmaceutics. New York. Marcel Dekker, Inc. 1979: 359-428.
- Martindale. Guía completa de consulta fármaco-terapéutica. Barcelona. Pharma editores S.L. 2003: 585-586. ISBN: 84-95993-00-7.
- Marvola M, Hannula AM, Ojantakanen S, Westermarck E, Rajamäki M. Effect of sodium bicarbonate and sodium starch glycolate on the in vivo disintegration of hard gelatin capsules – a radiological study in the dog. Acta Pharm Nord. 1989; 1 (6): 355–362.
- Mattsson S, Nyström C. Evaluation of strength-enhancing factors of a ductile binder in direct compression of sodium bicarbonate and calcium carbonate powders. Eur J Pharm Sci. 2000; 10 (1): 53–66.
- Mattsson S, Nyström C. Evaluation of critical binder properties affecting the compactability of binary mixtures. Drug Dev Ind Pharm. 2001; 27: 181–194.
- Mendes RW, Goll S, An CQ. Wet granulation: a comparison of Manni-Tab and mannitol. Drug Cosmet Ind. 1978; 122 (3): 36-44, 87–88.
- Michael A, Rombaut P, Verhoye A. Comparative evaluation of co-processed lactose and microcrystalline cellulose with their physical mixtures in the formulation of folic acid tablets. Pharm Dev Technol. 2002; 7(1): 79–87.
- Moldenhauer M, Nairn J. The control of ethyl cellulose microencapsulation using solubility parameters. J Control Release. 1992; 22: 205–218.

- Molokhia AM, Moustafa MA, Gouda MW. Effect of storage conditions on the hardness, disintegration and drug release from some tablet bases. *Drug Dev Ind Pharm.* 1982; 8: 283–292.
- Molokhia AM, Al-Shora HI, Hammad AA. Aging of tablets prepared by direct compression of bases with different moisture content. *Drug Dev Ind Pharm.* 1987; 13: 1933–1946.
- Montgomery DC. *Design and analysis of experiments.* Hoboken (NJ). John Wiley & Sons, Inc. 2013. ISBN 9781118146927.
- Mu X, Toby MJ, Stanforth JN. Investigations into the food effect on a polysaccharide dosage form. *Eur J Pharm Sci.* 1996; 4 (Suppl. 1): 184.
- Murty BSR, Kapoor JN, Smith FX. Levels of 5-hydroxymethylfurfural in dextrose injection. *Am J Hosp Pharm.* 1977; 34: 205–206.
- Nagvenkar SP. SUPAC – Scale-Up and Post Approval Changes. 2011. Disponible en: <http://es.slideshare.net/sonianagvenkar/supac>; último acceso: Julio 2014.
- Narisawa S, Yoshino H, Hirakawa Y, Noda K. Porosity-controlled ethyl cellulose film coating. IV. Evaluation of mechanical strength of porous ethyl cellulose film. *Chem Pharm Bull.* 1994; 42 (7): 1491–1495.
- Nesarikar VV, Vatsaraj N, Patel C, Early W, Pandey P, Sprockel O, Gao Z, Jerzewski R, Miller R, Levin M. Instrumented roll technology for the design space development of roller compaction process. *Int J Pharm.* 2012; 426: 116– 131.
- Newcombe AR, Watson K, Newcombe C. Biopharmaceutical process characterisation: Defining the design space. *Pharmaceutical Engineering.* 2008; 28 (2): 8-17.
- Newton JM, Razzo FN. Interaction of formulation factors and dissolution fluid and the in vitro release of drug from hard gelatin capsules. *J Pharm Pharmacol.* 1975; 27: 78P.
- Nogueira Prista L, Correia A, Mogardo R. *Técnica Farmacéutica e Farmacia Galénica.* Volumen I. 4ª Ed. Lisboa. Fundação Calouste Gulbenkian. 1981.
- O'Donnell K, Zwickovits M, Greene A, Calnan N. Quality Risk Management – Putting GMP Controls First. *J. of Pharm. Science & Technology.* 2012; Mayo/Junio.
- Ohm A. Process validation of Oral Solid Dosage forms: A semi-scientific overview. *Pharm Tech Eur.* 1997; 9 (10): 30-38.
- Olivero JJ. Formas compactadas de polvos: comprimidos y granulados. En: Helman J, editor. *Farmacotecnia teórica y práctica.* Tomo IV. México. Continental. 1982: 1687-1761.
- Omray A, Omray P. Evaluation of microcrystalline cellulose as a glidant. *Indian J Pharm Sci.* 1986; 48: 20–22.

- Otsuka M, Ohtani H, Otsuka K, Kaneniwa N. Effect of humidity on solid-state isomerization of various kinds of lactose during grinding. *J Pharm Pharmacol*. 1993; 45: 2–5.
- Ozturk AG, Ozturk SS, Palsson BO, Wheatley TA, Dressman JB. Mechanism of release from pellets coated with an ethyl cellulose-based film. *J Control Release*. 1990; 14(3): 203–213.
- Parab PV, Oh CK, Ritschel WA. Sustained release from Precirol (glycerol palmito-stearate) matrix. Effect of mannitol and hydroxypropyl methylcellulose on the release of theophylline. *Drug Dev Ind Pharm*. 1986; 12: 1309–1327.
- Paronen P. Behaviour of some direct compression adjuvants during the tableting process. *STP Pharma*. 1986; 2 (19): 682–688.
- Pascual J. Almotriptan in triptan-naïve patients: new evidence of benefits. *Cephalalgia*. 2008; Sep (28) Suppl 2: 14-20.
- Pascual J, Vila C, McGown CC. Almotriptan: a review of 10 years' clinical experience. *Expert Rev Neurother*. 2010; Oct 10 (10): 1505-1517. Review.
- Patel NR, Hopponen RE. Mechanism of action of starch as a disintegrating agent in aspirin tablets. *J Pharm Sci*. 1966; 55: 1065–1068.
- Pérez-Lozano P, Suñé-Negre JM, Miñarro M, Roig M, Fuster R, García-Montoya E, Hernández C, Ruhí R, Ticó JR. A new expert systems (SeDeM Diagram) for control batch powder formulation and preformulation drug products. *Eur J Pharm Biopharm*. 2006; 64: 351-359.
- Pesonen T, Paronen P. The effect of particle and powder properties on the mechanical properties of directly compressed cellulose tablets. *Drug Dev Ind Pharm*. 1990; 16 (1): 31-54.
- Pesonen T, Kanerva H, Hirvonen J, Nuuja T, Pohjola J, Rhodes T. Incompatibilities between chlorhexidine diacetate and some tablet excipients. *Drug Dev Ind Pharm*. 1995; 21: 747–752.
- Pirela Z. Uso de los sistemas de experto: ventajas y desventajas. [blogspot.com](http://zullyspirela.blogspot.com) [internet]. Disponible en: <http://zullyspirela.blogspot.com.es/2011/06/uso-de-los-sistemas-expertos-ventajas-y.html>; último acceso: Julio 2014.
- Podczek FK. Knowledge based system for the development of tablets. *Procedente de: 11th Pharmaceutical Technology Conference*. 1992; vol. I: 240-264.
- Pollock D, Sheskey P. Micronized ethylcellulose: opportunities in direct-compression controlled-release tablets. *Pharm Technol*. 1996; 20 (9): 120–130.
- Porter SC. Controlled-release film coatings based on ethylcellulose. *Drug Dev Ind Pharm*. 1989; 15 (10): 1495–1521.
- Pujara C. Granulation: Preparation, Evaluation & Control. *Procedente de: 5th Annual Garnet E. Peck Symposium; 2007 25 Octubre; West Lafayette (USA)*.

- Pyne A, Surana R, Suryanarayanan R. Crystallization of mannitol below T_g' during freeze-drying in binary and ternary aqueous systems. *Pharm Res.* 2002; 19: 901–908.
- Ramani RV, Patel MR, Patel SK. An expert system for drug preformulation in a pharmaceutical company. *Interfaces.* 1992; 22: 101-108.
- Ravikumar K, Sridhar B, Krishnan H, Singh AN. Almotriptan, an antimigraine agent, and its malate salt. *Acta Crystallogr C.* 2008; Jan 64 (Pt 1): o15-7.
- Rawlñins EA, editor. Bentley's textbook of pharmaceutics 8^a Ed. London. Baillière Tindall. 1977.
- Real Farmacopea Española, 3^a edición. Madrid. Ministerio de Sanidad y Consumo. 2005. Formas Farmaceuticas: Comprimidos.
- Real Farmacopea Española, 3^a edición. Madrid. Ministerio de Sanidad y Consumo. 2005. Monografía: 2.9.1: Disgregación de comprimidos y cápsulas.
- Real Farmacopea Española, 3^a edición. Madrid. Ministerio de Sanidad y Consumo. 2005. Monografía 2.9.3: Ensayo de disolución para formas orales sólidas.
- Real Farmacopea Española, 3^a edición. Madrid. Ministerio de Sanidad y Consumo. 2005. Monografía 2.9.5: Uniformidad de masa de las preparaciones presentadas en dosis únicas.
- Real Farmacopea Española, 3^a edición. Madrid. Ministerio de Sanidad y Consumo. 2005. Monografía 2.9.7: Friabilidad de los comprimidos no recubiertos.
- Rees JE, Rue PJ. Work required to cause failure of tablets in diametral compression. *Drug Dev Ind Pharm.* 1978; 4: 131–156.
- Reimerdes D, Aufmuth KP. Tableting with co-processed lactose–cellulose excipient. *Manuf Chem.* 1992; 63 (12): 21- 24.
- Riepma KA, Dekker BG, Lerk CF. The effect of moisture sorption on the strength and internal surface area of lactose tablets. *Int J Pharm.* 1992; 87: 149–159.
- Robbins H. Some Aspects of the Sequential Design of Experiments". *Bulletin of the American Mathematical Society.* 1952; 58 (5): 527–535.
- Robinson DH. Ethyl cellulose-solvent phase relationships relevant to coacervation microencapsulation processes. *Drug Dev Ind Pharm.* 1989; 15 (14–16): 2597–2620.
- Roig Farma, SAU. Ficha de seguridad de magnesio fosfato dibásico. Versión 1. 23 Febrero 2006.
- Rotteglia E. *Compresse Farmaceutiche.* 2^a Ed. Milán. Società editoriale farmaceutica. 1966.

- Rowe RC. The prediction of compatibility/incompatibility in blends of ethyl cellulose with hydroxypropyl methylcellulose or hydroxypropyl cellulose using 2-dimensional solubility parameter maps. *J Pharm Pharmacol*. 1986; 38: 214–215.
- Rowe RC, Upjohn NG. Formulating Pharmaceuticals using expert systems. *Pharmaceutical Technology International*. 1993; September: 46-52.
- Rowe RC, Upjohn NG. An expert system for the formulation of pharmaceutical tablets. *DTI Manufacturing Intelligence Newsletter*. 1993; 14: 13-15.
- Rowe RC, Sheskey PJ, Quinn ME, editores. *Handbook of Pharmaceutical Excipients*. 6th Edition. London (UK). The Pharmaceutical Press. 2009.
- Rubinstein MH. Tablets. En: Aulton ME, editor. *Pharmaceutics: the science of dosage forms design*. London. Churchill Livingstone. 1988.
- Rubinstein MH, Price EJ. In vivo evaluation of the effect of five disintegrants on the bioavailability of frusemide from 40 mg tablets. *J Pharm Pharmacol*. 1977; 29: 5P.
- Rudnic EM, Rhodes CT, Welch S, Bernardo P. Evaluations of the mechanism of disintegrant action. *Drug Dev Ind Pharm*. 1982; 8: 87–109.
- Rudnic EM, Kanig JL, Rhodes CT. Effect of molecular structure variation on the disintegrant action of sodium starch glycolate. *J Pharm Sci*. 1985; 74: 647–650. Doi: 10.1002/jps.2600740613.
- Sadeghi F, Ford JL, Rubinstein MH, Rajabi-Siahboomi AR. Study of drug release from pellets coated with surelease containing hydroxypropylmethylcellulose. *Drug Dev Ind Pharm*. 2001; 27 (5): 419–430.
- Saettone MF, Perini G, Rijli P, Rodriguez L, Cini M. Effect of different polymer-plasticizer combinations on 'in vitro' release of theophylline from coated pellets. *Int J Pharm*. 1995; 126: 83–88.
- Sakata Y, Shiraishi S, Otsuka M. Characterization of dehydration and hydration behavior of calcium lactate pentahydrate and its anhydrate. *Colloids Surf B Biointerfaces*. 2005; 46: 135–141.
- Sakr AM, Elsabbagh HM, Emara KM. Sta-Rx 1500 starch: a new vehicle for the direct compression of tablets. *Arch Pharm Chem (Sci)*. 1974; 2: 14–24.
- Salazar R, editor. *Tecnología Farmacéutica Industrial*. Barcelona. Romargraf S.A. 2003.
- Salazar R, editor. *Cualificación y Validación*. Barcelona. Romargraf S.A. 2007.
- Salazar R, editor. *Fabricación y Control de Formas Farmacéuticas Recubiertas*. Barcelona. Síntesis. 2010.
- Saleh SI, Aboutaleb A. Evaluation of some water soluble lubricants for direct compression. *Lab Pharm Prob Tech*. 1984; 32: 588–591.

- Sandrini G, Perrotta A, Arce-Leal NL, Buscone S, Nappi G. Almotriptan in the treatment of migraine. *Neuropsychiatric Disease and Treatment*. 2007; 3(6): 799–809.
- Sarisuta N, Sirithunyalug J. Release rate of indomethacin from coated granules. *Drug Dev Ind Pharm*. 1988; 14 (5): 683–687.
- Saurí J, Millán D, Suñé-Negre, JM, Pérez-Lozano P, Sarrate R, Fábregas A, Carrillo C, Miñarro M, Ticó JR, García-Montoya E. The use of the SeDeM diagram expert system for the formulation of Captopril SR matrix tablets by direct compression. *Int J Pharm*. 2014; 461 (1-2): 38-45.
- Schlack H, Bauer-Brandl A, Schubert R, Becker D. Properties of Fujicalin®, a new modified anhydrous dibasic calcium phosphate for direct compression: comparison with dicalcium phosphate dihydrate. *Drug Dev Ind Pharm*. 2001; 27(8): 789–801.
- Schmidt PC, Herzog R. Calcium phosphates in pharmaceutical tableting 1: physico-pharmaceutical properties. *Pharm World Sci*. 1993; 15 (3): 105–115. Referencia (a).
- Schmidt PC, Herzog R. Calcium phosphates in pharmaceutical tableting 2: comparison of tableting properties. *Pharm World Sci*. 1993; 15 (3): 116–122. Referencia (b).
- Schmidt PC, Vortisch W. [Influence of manufacturing method of fillers and binders on their tableting properties: comparison of 8 commercially available sorbitols]. *Pharm Ind*. 1987; 49: 495–503 [in German].
- Schwartz JB, Martin ET, Dehner EJ. Intragranular starch: comparison of starch USP and modified cornstarch. *J Pharm Sci*. 1975; 64: 328–332.
- Seager H. Drug development products and the Zydis fast dissolving dosage form. *J Pharm Pharmacol*. 1998; 50: 375–382.
- Sekulovic D, Tufegdžic N, Birmanević M. The investigation of the influence of Explotab on the disintegration of tablets. *Pharmazie* 1986; 41: 153–154.
- Serra MD, Robles LV. Compaction of agglomerated mixtures of calcium carbonate and microcrystalline cellulose. *Int J Pharm*. 2003; 258 (1–2): 153–164.
- Seth BB, Bandeling FJ, Shangraw RF. Compressed tablets. En: Lieberman HA, Lachman L, editores. *Pharmaceutical dosage forms: Tablets*. Vol I. New York. Marcel Dekker, Inc. 1980: 86-109.
- Shah NH, Stiel D, Weiss M, Infeld MH, Malick AW. Evaluation of two new tablet lubricants sodium stearyl fumarate and glyceryl behenate. Measurement of physical parameters (compaction, ejection and residual forces) in the tableting process and the effect on the dissolution rate. *Drug Dev Ind Pharm*. 1986; 12: 1329– 1346.
- Shangraw RF, Wallace JW, Bowers FM. Morphology and functionality in tablet excipients for direct compression: part II. *Pharm Technol*. 1981; 5 (10): 44–60.

- Shewhart WA. Statistical Method from the Viewpoint of Quality. 1939. Control ISBN 0-486-65232-7.
- Shiromani PK, Clair J. Statistical comparison of high-shear versus low-shear granulation using a common formulation. *Drug Dev Ind Pharm.* 2000; 26: 357–364.
- Sinka IC, Motazedian F, Cocks ACF, Pitt KG. The effect of processing parameters on pharmaceutical tablet properties. *Powder Technology.* 2009; 189: 276–284.
- Small LE, Augsburg LL. Aspects of the lubrication requirements for an automatic capsule filling machine. *Drug Dev Ind Pharm.* 1978; 4: 345–372.
- Snee RD. Think Strategically for design of experiments success. *BioProcess International.* 2011; Marzo: 18-25.
- Stewart AG, Grant DJ, Newton JM. The release of a model low-dose drug (riboflavine) from hard gelatin capsule formulations. *J Pharm Pharmacol.* 1979; 31: 1–6.
- Sturgeon RJ, Athanikar NK, Harbison HA, Henry RS, Jurgens RW Jr, Welco AD. Degradation of dextrose during heating under simulated sterilization. *J Parenter Drug Assoc.* 1980; 34: 175–182.
- Suneetha A, Syama Sunda B. A Validated RP HPLC Method for Estimation of Almotriptan Malate in Pharmaceutical Dosage Form. *Journal of the Chinese Chemical Society.* 2010; 57: 1067-1070.
- Suñé-Negre JM, Roig-Carreras M, Fuster-García R, Hernández-Pérez C, Ruhí-Rovira R, García-Montoya E, Miñarro-Carmona M, Pérez-Lozano P, Ticó-Grau JR. Nueva metodología de preformulación galénica para la caracterización de sustancias en relación a su viabilidad para la compresión: Diagrama SeDeM. *Cien. Technol. Pharm.* 2005; 3: 125-136.
- Suñé-Negre JM, Pérez-Lozano P, Miñarro M, Roig M, Fuster R, Hernández C, Ruhí R, García-Montoya E, Ticó JR. Application of the SeDeM Diagram and a new mathematical equation in the design of direct compression tablet formulation. *Eur. J. Pharm. Biopharm.* 2008; 69: 1029-1039.
- Suñé-Negre JM, García-Montoya E, Pérez-Lozano P, Aguilar-Díaz JE, Roig-Carreras M, Fuster-García R, Miñarro-Carmona M, Ticó JR. Diagram SeDeM: A new Expert System for the Formulations of drugs in Solid Form. En Vizureanu P, editor. *Expert Systems for Human, Materials and Automation.* Rijeka (Croatia). InTech. 2011: 17-34. ISBN 978-953-307-334-7. Referencia (a).
- Suñé-Negre JM, Pérez-Lozano P, Miñarro-Carmona M, Roig-Carreras M, Fuster-García R, Hernández-Pérez C, Ruhí R, García-Montoya E, Ticó JR. Optimization of parameters of the SeDeM diagram expert system: Hausner index (IH) and relative humidity (%RH). *Eur J Pharm Biopharm.* 2011; 79: 464-472. Referencia (b).

- Suñé-Negre JM. Aplicación del Diagrama SeDeM y nueva ecuación matemática en el diseño y formulación de comprimidos. En Salazar Macian R, editor. Tertulias tecnológicas con los amigos del profesor Ramón Salazar. Barcelona. Talleres Gráficos Vigor S.A. 2012: 371-394.
- Suñé-Negre JM, Roig-Carreras M, Fuster-García R, García-Montoya E, Pérez-Lozano P, Aguilar-Díaz JE, Miñarro-Carmona M, Tico JR. Diagram SeDeM: An expert system for preformulation, characterization and optimization of tablets obtained for direct compression. En Aguilar Díaz JE, editor. Formulations tools for pharmaceutical development. Cambridge (UK). Woodhead Publishing Limited. 2013: 109-135.
- Surén G. Evaluation of lubricants in the development of tablet formula. Dansk Tidsskr Farm. 1971; 45: 331–338.
- Suzuki T, Nakagami H. Effect of crystallinity of microcrystalline cellulose on the compactability and dissolution of tablets. Eur J Pharm Biopharm. 1999; 47: 225–230.
- Tazón F. Estado actual y perspectivas futuras. Procedente de: Institute for Life Long Learning (IL3): Tecnología Analítica de Procesos (PAT). 2007 Marzo; Barcelona (España).
- Thibert R, Hancock BC. Direct visualization of superdisintegrant hydration using environmental scanning electron microscopy. J Pharm Sci. 1996; 85: 1255–1258.
- Thwaites PM, Mashadi AB, Moore WD. An investigation of the effect of high speed mixing on the mechanical and physical properties of direct compression lactose. Drug Dev Ind Pharm. 1991; 17: 503–517.
- Turner J. Product formulation expert system DTI Manufacturing. Intelligence Newsletter. 1992; 8: 12-14.
- Underwood TW, Cadwallader DE. Influence of various starches on dissolution rate of salicylic acid from tablets. J Pharm Sci. 1972; 61: 239–243.
- US FDA: United States - Food and Drug Administration. Guidance for Industry PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. Department of Health and Human Services, U.S. 2004. Disponible en: <http://www.fda.gov/downloads/Drugs/Guidances/ucm070305.pdf>; último acceso: Junio 2014.
- US FDA: United States - Food and Drug Administration. Pharmaceutical cGMPs for the 21st Century - A Risk-Based Approach, Final Report. Department of Health and Human Services, U.S. 2004. Disponible en: http://www.fda.gov/cder/gmp/gmp2004/GMP_finalreport2004.htm; último acceso: Junio 2014.
- USP: United States Pharmacopoeia. Rockville (Maryland). United States Pharmacopoeial Convention, Inc. 2009. Authorized USP pending Monograph: Almotriptan tablets. Version 1.

- USP: United States Pharmacopoeia. Rockville (Maryland). United States Pharmacopoeial Convention, Inc. 2011. Authorized USP pending Monograph: Almotriptan malate. Version 2.
- USP30: United States Pharmacopoeia 30 – National Formulary 25. Rockville (Maryland). United States Pharmacopoeial Convention, Inc. 2007. General Chapters: <711> Dissolution.
- USP31: United States Pharmacopoeia 31 – National Formulary 26. Rockville (Maryland). United States Pharmacopoeial Convention, Inc. 2008. USP Monographs: <Powder flow>.
- USP32: United States Pharmacopoeia 32 – National Formulary 27. Rockville (Maryland). United States Pharmacopoeial Convention, Inc. 2009. Official monographs: Sodium Starch Glycolate: 6183-6185.
- USP37: United States Pharmacopoeia 37 – National Formulary 32. Rockville (Maryland). United States Pharmacopoeial Convention, Inc. 2014. General Chapters: <1151> Pharmaceutical dosage forms.
- USP37: United States Pharmacopoeia 37 – National Formulary 32. Rockville (Maryland). United States Pharmacopoeial Convention, Inc. 2014. Official monographs: Calcium carbonate: 2074-2076.
- USP37: United States Pharmacopoeia 37 – National Formulary 32. Rockville (Maryland). United States Pharmacopoeial Convention, Inc. 2014. <NF Starch>: 6201-6203.
- Vademecum: Almotriptán [internet]. Disponible en: <http://www.vademecum.es/principios-activos-almotriptan-n02cc05>; ultimo acceso Marzo 2014.
- Valizdeh H, Nokhodchi A, Qarakhari N, Zakeri-Milani P, Azarmi S, Hassanzadeh D, Löbenberg R. Physicochemical characterization of solid dispersions of indometacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit (R) E100. Drug Dev Ind Pharm. 2004; 30 (3): 303–317.
- Vanderbist F, Wery B, Moyano-Pavon I, Moes AJ. Optimization of a dry powder inhaler formulation of nalcystelyn, a new mucoactive agent. J Pharm Pharmacol. 1999; 51 (11): 1229–1234.
- Vesper JL. Risk Assessment and Risk Management in the Pharmaceutical Industry. Davis Healthcare International Publishing. 2006
- Vila Jato JL, editor. Tecnología Farmacéutica. Volumen II: Formas Farmacéuticas. Madrid. Síntesis. 1997.
- Viscasillas A. Aportación al diseño de un nuevo excipiente coprocesado para compresión directa. Tesis doctoral. Facultad de Farmacia. Barcelona. Universidad de Barcelona. 2008.
- Voight R, Bornschein M. Tratado de tecnología farmacéutica. Zaragoza. Acibia.1982.

- Vromans H, de Boer AH, Bolhuis GK, Lerk CF, Kussendrager KD. Studies on the tableting properties of lactose: the effect of initial particle size on binding properties and dehydration characteristics of α -lactose monohydrate. En: Rubinstein MH, editor. *Pharmaceutical Technology: Tableting Technology*, vol. 1. Chichester. Ellis Horwood. 1987: 31–42.
- Wagner KJ, Dressler JA. A corn starch/ α -lactose monohydrate compound as a new directly compressible excipient. *Pharm Ind.* 2002; 64(9): 992–999.
- Wallace JW, Capozzi JT, Shangraw RF. Performance of pharmaceutical filler/binders as related to methods of powder characterization. *Pharm Technol.* 1983; 7 (9): 94–104.
- Wan LSC, Prasad KPP. Uptake of water by excipients in tablets. *Int J Pharm.* 1989; 50: 147–153.
- Weiner M, Bernstein IL, editores. *Adverse Reactions to Drug Formulation Agents: A Handbook of Excipients*. New York. Marcel Dekker. 1989: 93–94.
- WHO: World Health Organization. The international pharmacopoeia. Document QAS/09.324/Final. March 2011. Revision of monograph on tablets.
- Wikipedia: Almotriptán [Internet]. Disponible en: <http://es.wikipedia.org/wiki/Almotriptán>; último acceso: Marzo 2014.
- Wikipedia: Sistema de experto [Internet]. Disponible en: http://es.wikipedia.org/wiki/Sistema_experto; último acceso: Febrero 2014.
- Wing WT. An examination of the decomposition of dextrose solution during sterilisation. *J Pharm Pharmacol.* 1960; 12: 191T–196T.
- Wirth DD, Baertschi SW, Johnson RA, Maple SR, Miller SR, Hallenbeck DK, Gregg SM. Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine. *J Pharm Sci.* 1998; 87: 31–39.
- Wong LW, Pilpel N. The effect of particle shape on the mechanical properties of powders. *Int. J. Pharm.* 1990; 59: 145-154.
- Wood M. Expert systems save formulation time. *Laboratory Equipment Digest.* 1991; diciembre: 17-19.
- Woyna-Orlewicz K, Jachowicz R. Analysis of wet granulation process with Plackett-Burman design – Case study. *Acta Poloniae Pharmaceutica - Drug Research.* 2011; 68(5): 725-733.
- Wu JS, Ho H, Sheu MT. A statistical design to evaluate the influence of manufacturing factors on the material properties and functionalities of microcrystalline cellulose. *Eur J Pharm Sci.* 2001; 12 (4): 417–425.
- Wurster DE, Peck GE, Kildsig DO. A comparison of the moisture adsorption–desorption properties of corn starch USP, and directly compressible starch. *Drug Dev Ind Pharm.* 1982; 8: 343–354.
- Yin T. A guide to blend uniformity. *Journal of GxP compliance.* 2007. Volumen 12. Número 1. 46-51.

- York P. Studies of the effect of powder moisture content on drug release from hard gelatin capsules. *Drug Dev Ind Pharm.* 1980; 6: 605–627.
- Yoshinari T, Forbes RT, York P, Kawashima Y. Improved compaction properties of mannitol after a moisture induced polymorphic transition. *Int J Pharm.* 2003; 258(1–2): 121–131.
- Yu LX. Pharmaceutical quality by design: product and process development, understanding and control. *Pharm Res.* 2008; vol. 25 (4): 781-791.
- Zuurman K, Riepma KA, Bolhuis GK, Vromans H, Lerk C. The relationship between bulk density and compactibility of lactose granulations. *Int J Pharm.* 1994; 102: 1–9.

